OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion
COAV101A12308
Phase 3 small_molecule active
Quick answer
OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion for Spinal Muscular Atrophy is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Spinal Muscular Atrophy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active